Skip to main content
. 2012 Apr 2;109(16):6187–6192. doi: 10.1073/pnas.1203479109

Fig. 1.

Fig. 1.

IL-15 and simultaneous blockade of CTLA-4 and PD-L1 protected animals against tumor growth. (A) Growth curves illustrate in vivo growth rates of TRAMP-C2 tumors associated with diverse treatments. Tumor sizes shown represent means ± SEM, n = 10. (B) Kaplan-Meier survival curves illustrate survivals of mice with treatments. (C) mIL-15 combined with anti-IL-10/anti-TGF-β antibodies did not inhibit tumor growth beyond that achieved with IL-15 treatment alone. n = 10. (D) Tumor lysis activity was tested on day 21; TRAMP-C2 cells were used as the target cells. EL4 cells were used as control. Tumor-specific CD8 T-cell target cell killing was detected. *P < 0.05, lysis activity against TRAMP-C2 compared with PBS; †P < 0.05, lysis activity against TRAMP-C2 compared with other mIL-15 involved groups. (E) Splenic CD8 T cells were stimulated with SNC9-H8 or OVA peptide and cultured with irradiated splenocytes as APCs. IFN-γ secretion was measured by ELISA. Data represent five independent experiments. *P < 0.05. (F) Tumor-infiltrating cells were separated and stimulated with SNC9-H8 peptide. IFN-γ secretion was detected by ELISA. Data represent two experiments. *P < 0.05.